Separate strategic need from market pressure
This October 2024 opinion argues that simultaneous restructuring and R&D cuts across large pharmaceutical companies can amplify industry disruption. The author questions whether comparisons with high-growth technology businesses encourage unrealistic expectations for a mature sector.
Improve with precision
Evaluate portfolio balance, patent timing, and the mix of scientific risk before redesigning R&D. Apply cost reduction where it creates durable value rather than requiring every function to meet an identical percentage target.
The article favors continuous operational improvement and careful resource choices over reactions aimed chiefly at near-term stock performance. Its thesis is a strategic argument, not an established explanation for industry-wide performance. Companies should assess their own competitive position and operating evidence before following a broad prescription.